Verition Fund Management
ALGS icon

Verition Fund Management’s Aligos Therapeutics ALGS Stock Holding History

Verition Fund Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Hold
18,887
– – ﹤0.01% 1906
2026
Q1 		$140K Sell
18,887
-52,367
-73% -$397K ﹤0.01% 2001
2025
Q4 		$664K Buy
+71,254
New +$672K ﹤0.01% 2456

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Verition Fund Management's ALGS Position: Q2 2026 in Review

Verition Fund Management held its Aligos Therapeutics (ALGS) position steady in Q2 2026 at 18,887 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #1906.

Verition Fund Management first reported a position in ALGS in Q4 2025 and has held it in 3 quarters since. The position peaked at $664K in Q4 2025. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • Verition Fund Management held 18,887 shares of Aligos Therapeutics worth $109K as of Q2 2026.
  • Verition Fund Management left its Aligos Therapeutics share count unchanged in Q2 2026.
  • Aligos Therapeutics made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1906 holding.
  • Verition Fund Management first reported a position in Aligos Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Verition Fund Management's Aligos Therapeutics position peaked at $664K in Q4 2025.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.